Focus: Moderna is a Cambridge-based mRNA therapeutic company with ~5,900 employees that pioneered RNA vaccine technology and commercialized COVID-19 vaccines at scale. The company operates as a public biotech leader in vaccine development with emerging oncology and rare disease programs.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Hot — 142 jobs added in 30d
Net +82 (142 new, 60 removed). Aggressive expansion phase.
Strong for mRNA specialists and platform technologists, but evaluate financial stability carefully given FY2025 losses and COVID revenue cliff.
Early commercial success in RSV market with multiple Phase 2/3 trials active, representing core vaccine diversification strategy.
Help build intelligence for Moderna
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Moderna's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Next-generation COVID booster candidate in launch phase, competing in saturated pandemic vaccine market.
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting - BioPharma Dive
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting BioPharma Dive
Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile - CNBC
Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile CNBC
Pfizer vs Moderna: Only One Pharma Giant Is a Winner in the Post-Covid Era - MSN
Pfizer vs Moderna: Only One Pharma Giant Is a Winner in the Post-Covid Era MSN
Hantavirus Stirs Vaccine Skeptics, Moderna Questions, Prediction Conspiracy - Newsweek
Hantavirus Stirs Vaccine Skeptics, Moderna Questions, Prediction Conspiracy Newsweek
Hantavirus Revives COVID-Era Anti-Vaxxer Fears - Newsweek
Hantavirus Revives COVID-Era Anti-Vaxxer Fears Newsweek
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - ACCESS Newswire
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 ACCESS Newswire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.
Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo